Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors.
World J Gastroenterol
; 30(21): 2748-2750, 2024 Jun 07.
Article
em En
| MEDLINE
| ID: mdl-38899330
ABSTRACT
In this editorial, we offer a summary of the risk associated with hepatitis B reactivation (HBVr) in the setting of both solid and hematologic malignancies treated with Bruton tyrosine kinase (BTK) inhibitors, with insights derived from current studies. Furthermore, we emphasize the critical need for a framework regarding robust risk evaluation in patients undergoing such treatments. This framework is essential for identifying those at increased risk of HBVr, enabling healthcare providers to implement proactive measures to prevent reactivation and ensure the safe administration of BTK inhibitor therapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ativação Viral
/
Vírus da Hepatite B
/
Inibidores de Proteínas Quinases
/
Tirosina Quinase da Agamaglobulinemia
Limite:
Humans
Idioma:
En
Revista:
World J Gastroenterol
Ano de publicação:
2024
Tipo de documento:
Article